“Sweat equity takes on a whole new meaning when you’re networking in a hot room,” says Chad Messer, a managing director at US ...

Shares of the U.S.-listed Chinese immuno-oncology company I-Mab (NASDAQ: IMAB) offer strong upside potential, according to a Needham analyst. The I-Mab Analyst: Chad Messer initiated coverage of I ...

Lake Street analyst Chad Messer initiated coverage of Immunome (IMNM) with a Buy rating and $23 price target The company’s lead clinical program, varegacestat for desmoid tumors, is not an ...

With the positive results, Sarepta Therapeutics will seek approval from the Food and Drug Administration later this year for a drug, to treat the Duchenne muscular dystrophy.

Enthusiasts say high-temperature sessions sharpen focus, improve health, and offer a chance to build contacts. It’s a far cry ...

Shares of the U.S.-listed Chinese immuno-oncology company I-Mab IMAB offer strong upside potential, according to a Needham analyst. The I-Mab Analyst: Chad Messer initiated coverage of I-Mab ...